Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils
Granulocytes are important in the pathogenesis of several inflammatory diseases. Apoptosis is pivotal in the resolution of inflammation. Apoptosis in malignant cells is induced by histone deacetylase (HDAC) inhibitors, whereas HDAC inhibitors do not usually induce apoptosis in non-malignant cells. The aim of the present study was to explore the effects of HDAC inhibitors on apoptosis in human eosinophils and neutrophils.
Apoptosis was assessed by relative DNA fragmentation assay, annexin-V binding, and morphologic analysis. HDAC activity in nuclear extracts was measured with a nonisotopic assay. HDAC expression was measured by real-time PCR.
A HDAC inhibitor Trichostatin A (TSA) induced apoptosis in the presence of survival-prolonging cytokines interleukin-5 and granulocyte-macrophage colony stimulating factor (GM-CSF) in eosinophils and neutrophils. TSA enhanced constitutive eosinophil and neutrophil apoptosis. Similar effects were seen with a structurally dissimilar HDAC inhibitor apicidin. TSA showed additive effect on the glucocorticoid-induced eosinophil apoptosis, but antagonized glucocorticoid-induced neutrophil survival. Eosinophils and neutrophils expressed all HDACs at the mRNA level except that HDAC5 and HDAC11 mRNA expression was very low in both cell types, HDAC8 mRNA was very low in neutrophils and HDAC9 mRNA low in eosinophils. TSA reduced eosinophil and neutrophil nuclear HDAC activities by ~50-60%, suggesting a non-histone target. However, TSA did not increase the acetylation of a non-histone target NF-κB p65. c-jun-N-terminal kinase and caspases 3 and 6 may be involved in the mechanism of TSA-induced apoptosis, whereas PI3-kinase and caspase 8 are not.
HDAC inhibitors enhance apoptosis in human eosinophils and neutrophils in the absence and presence of survival-prolonging cytokines and glucocorticoids.
KeywordsChronic Obstructive Pulmonary Disease Glucocorticoid Budesonide Nuclear Extract Fluticasone
List of abbreviations
Chronic obstructive pulmonary disease
Granulocyte-macrophage colony-stimulating factor
RKKRRQRRR-amide, negative control for L-JNKI1
Eosinophils are important inflammatory cells involved in the pathogenesis of asthma and exacerbations of chronic obstructive pulmonary disease (COPD) . Accumulation and activation of neutrophils at the inflamed site is involved in the pathogenesis of COPD, severe asthma and asthma exacerbations . The process of apoptosis of granulocytes is believed to be pivotal in the resolution of inflammation, since it determines the rapid clearance of intact senescent eosinophils and neutrophils, thus providing an injury-limiting granulocyte clearance mechanism [2, 3]. Eosinophil and neutrophil apoptosis can be modulated by glucocorticoids and death receptors i.e. Fas and inhibited by survival-prolonging cytokines such as interleukin-5 (IL-5) and granulocyte-macrophage colony-stimulating factor (GM-CSF) [2, 3]. We, and others, have previously shown that eosinophil apoptosis is delayed in patients with asthma or inhalant allergy [4, 5, 6]. However, the mechanisms of apoptosis in these cells remain largely unknown. In fact, it is not even known whether the main event controlling eosinophil apoptosis is upregulation or downregulation of genes .
Histone acetylation regulates inflammatory gene expression and also plays a role in diverse functions such as DNA repair and cell proliferation and apoptosis [7, 8]. In the resting cell, DNA is tightly compacted around core histones. Specific residues within the N-terminal tails of histones can be posttranslationally modified by acetylation, leading to release of the tightly wound DNA. Conversely, histone deacetylation is thought to re-establish the tight nucleosomal structure [7, 8]. Histone acetylation is regulated by a dynamic balance between histone acetyltransferases (HAT) and histone deacetylases (HDAC). Changes in histone acetylation patterns have been reported in many human diseases, particularly cancer, and investigators have used HDAC inhibitors against many malignancies. HDAC inhibitors induce apoptotic cell death in a number of tumor cell types [9, 10]. In contrast, normal cells are usually resistant to cell death caused by HDAC inhibitors [9, 10].
However, recent in vivo data in animal models suggest that HDAC inhibitors may have potential to act as anti-inflammatory and anti-allergic agents. For example, evidence from an adjuvant-induced arthritis-model suggests that HDAC inhibitors may be useful in rheumatoid arthritis . Recently, Choi and coworkers  demonstrated that trichostatin A (TSA) blocked ovalbumin (OVA) -induced airway hyper-responsiveness, as well as reduced the numbers of eosinophils in lavage fluid. Even though HDAC inhibitors do not usually induce apoptosis in non-malignant cells, the promising in vivo findings prompted us to test the effects of HDAC inhibitors on apoptosis of terminally differentiated primary cells such as human eosinophils and neutrophils.
For neutrophil experiments blood was obtained from healthy donors. For eosinophil experiments, blood (50-100 ml) was obtained from eosinophilic individuals. However, patients with hypereosinophilic syndrome were excluded. All subjects gave informed consent to a study protocol approved by the ethical committee of Tampere University Hospital (Tampere, Finland).
Neutrophil and eosinophil isolation
Neutrophils from venous blood were isolated under sterile conditions as previously reported [13, 14]. Neutrophil populations with purity of >98% were accepted for the experiments. The neutrophils were resuspended at 2 × 106 cells/ml, cultured for 16 h (37°C; 5% CO2) in RPMI 1640 (Dutch modification) with 10% fetal calf serum plus antibiotics. Eosinophils were purified by using immunomagnetic anti-CD16 antibody conjugated beads as previously described [5, 15, 16, 17]. The purity of eosinophil population was > 99%. The eosinophils were resuspended at 1 × 106 cells/ml, cultured (37°C, 5% CO2) for 18 h (morphological and Annexin-V assays) or 40 h (relative DNA fragmentation assay) in the absence or presence of cytokines, glucocorticoids and HDAC inhibitors in RPMI 1640 (Dutch modification) with 10% fetal calf serum plus antibiotics in 96-well plates.
J774.2 macrophages (The European Collection of Cell Cultures, Porton Down, Wiltshire, UK) were cultured at 37°C, 5% CO2 atmosphere, in Dulbecco's Modified Eagle's Medium with Ultraglutamine 1 (DMEM/U1) supplemented with 5% of heat inactivated foetal bovine serum, penicillin (100 U/ml), streptomycin (100 μg/ml) and amphotericin B (250 ng/ml). Cells were seeded on 24 well plates and grown to confluence prior to experiments. Cells were cultured for 24 h in the presence or absence of various concentrations of TSA or lipopolysaccharide (LPS; 10 ng/ml) and ammonium pyrrolidinedithiocarbamate (PDTC; 100 μM), whereafter medium was removed, cells were washed once with phosphate-buffered saline (PBS) and double-stained with Annexin-V and PI.
Apoptosis was determined by propidium iodide staining of DNA fragmentation and flow cytometry (FACScan, Becton Dickinson, San Jose, CA) as previously described [15, 16, 17]. The cells showing decreased relative DNA content were considered apoptotic [15, 16]. Annexin V-binding assay was performed as previously described [14, 16] and cells showing positive staining with Annexin-V (i.e. both early apoptotic Annexin V+ve/PI-ve and late apoptotic/secondary necrotic cells: Annexin V+ve/PI+ve) were considered to be apoptotic. For morphological analysis, eosinophils or neutrophils were centrifuged onto cytospin slides (1000 rpm, 7 min) and stained with May-Grünwald-Giemsa after fixation in methanol. The cells showing typical features of apoptosis such as cell shrinkage, nuclear coalescence and nuclear chromatin condensation were considered as apoptotic [5, 15, 16].
Eosinophils were suspended at 106 cells/ml and cultured at +37°C for 1 h in the absence and presence of DMSO (solvent control), TSA (330 nM) or GM-CSF (0.1 ng/ml). Thereafter the samples were centrifuged at 1000 g for 1 min. The cell pellet was lysed by incubating for 15-30 min in 40 μl of ice-cold RIPA buffer with protease inhibitors. The sample was centrifuged at 12000 g for 5 min and the debris was carefully removed. Samples were mixed into SDS (sodium dodecyl sulfate)-containing loading buffer and stored at -20°C until the Western blot analysis. The protein sample (25-30 μg) was loaded onto 10% SDS-polyacrylamide electrophoresis gel and electrophoresed for 2 h at 120 V. The separated proteins were transferred to Hybond enhanced chemiluminescence nitrocellulose membrane (Amersham Biosciences UK, Ltd., Little Chalfont, Buckinghamshire, UK) with a semidry blotter at 2 mA cm-2 for 60 min. After transfer, the membranes were blocked by 5% bovine serum albumin (BSA) in TBST (20 mM Tris base pH 7.6, 150 mM NaCl, 0.1% Tween-20) for 1 h at room temperature and incubated with the specific primary antibody overnight at +4°C in the blocking solution. The membrane was thereafter washed 3× with TBST for 5 min, incubated for 30 min at room temperature with the secondary antibody in the blocking solution and washed 3× with TBST for 5 min. Bound antibody was detected by using SuperSignal West Dura chemiluminescent substrate (Pierce, Cheshire, UK) and FluorChem 8800 imaging system (Alpha Innotech Corporation, San Leandro, CA, USA). The chemiluminescent signal was quantified by using the FluorChem software version 3.1.
HDAC colorimetric activity assay
Nuclear extracts were prepared from 5 × 106 cells using a modification of method of Dignam et al . Briefly, isolated cells were washed with cold PBS and suspended in hypotonic buffer A (20 mM HEPES-KOH, pH 7.9, 3.0 mM MgCl2, 20 mM KCl and protease inhibitor mixture). After incubation for 30 min on ice, 0.2 volumes of 10% igepal CA-30 (v/v) was added, and the cells were vortexed for 30 s. Eosinophils were further processed by Dounce tissue homogenizer. Following centrifugation at 12,000 g for 10 s, the supernatant was discarded and the pellet was washed in 100 μl of buffer A without Igepal and re-centrifuged. The pelleted nuclei were resuspended in buffer C (40 mM HEPES-KOH, pH 7.9, 50% glycerol, 840 mM NaCl, 3 mM MgCl2, 0.2 mM EDTA and protease inhibitor cocktail tablet solution) and incubated for 20 min on ice. Nuclei were vortexed for 1 min and nuclear extracts were obtained by centrifugation at 12,000 g for 2 min, 4°C and stored at -76°C until use.
HDAC colorimetric activity assay was carried out according to the manufacturer's instructions. HDAC inhibitors and assay buffer were mixed to the wells of the microtiter plate. Nuclear extracts were added to appropriate wells and equilibrated to assay temperature (37°C). Color de Lys™ substrate was added and mixed in each well to initiate HDAC reactions and incubated at 37°C for 30 min. Color de Lys™ developer was added to stop HDAC reaction. The mixture was incubated at 37°C for 15 min and read in microtiter-plate reader (Wallac, Turku, Finland) at 405 nm.
To isolate mRNA from human eosinophils and neutrophils, the cells were first sedimented whereafter TRI REAGENT (1.0 ml/5 × 106 eosinophils) was added. mRNA was isolated according to the manufacturer's instructions and reverse transcription of RNA to cDNA was performed as described previously .
Gene transcript levels of HDAC1 to 11 and the housekeeping genes glyceraldehydes-3 phosphate dehydrogenase (GAPDH) and GLB2L1 were quantified by real-time PCR using a Taqman master mix (Applied Biosystems, Foster City, CA) on a Rotor-Gene 3000 PCR apparatus (Corbett Research, N.S.W., Australia). The primer pairs were purchased from Applied Biosystems. Variations in cDNA concentration between different samples were corrected using the housekeeping gene. The relative amount of gene transcript present was calculated and normalized by dividing the calculated value for the gene of interest by the housekeeping gene value.
Reagents were obtained as follows: apicidin, MC-1293 and MS-275 (Alexis, Lausen, Switzerland), CD95 monoclonal antibody (clone CH-11; Immunotech, Marseille, France), NF-kB p65 and acetyl-NF-kB p65 (Lys310) antibodies (Cell Signaling Technology, Inc., Danvers, USA), fluticasone, igepal CA-630, LPS, PDTC and trichostatin A (Sigma Chemical Co., St. Louis, MO, USA), Z-VE(OMe)ID(OMe)-FMK, Z-D(OMe)QMD(OMe)-FMK, IETD-CHO, Q-VD-OPh and LY294002 (Calbiochem, San Diego, USA), HDAC colorimetric activity kit (Biomol, Plymouth Meeting, USA), mometasone (Schering-Plough, Kenilworth, NJ), DMEM/U1 (Lonza Verviers SPRL, Verviers, Belgium), penicillin, streptomycin and amphotericin (Invitrogen, Paisley UK), wortmannin (Merck, Darmstadt, Germany) and TRI REAGENT (Molecular Research Center, Inc., Cincinnati, OH). Other reagents were obtained as previously described [5, 13, 14, 15, 16, 17, 19]. Stock solutions of budesonide (50 mM) were prepared in ethanol. The final concentration of ethanol in the culture was 0.2%. Stock solutions of HDAC inhibitors were prepared in DMSO. The final concentration of DMSO in the culture was 0.5%. A similar concentration of DMSO was used in control experiments.
Results are expressed as Mean ± SEM. The EC50 was defined as the concentration of drug producing 50% of its maximal effect. Statistical significance was calculated by analysis of variance for repeated measures supported by Student-Newman-Keuls multiple comparisons test or Dunnett test. HDAC expression levels obtained by quantitative PCR were compared using Mann-Whitney U-test. Differences were considered significant when P < 0.05.
HDAC inhibitors enhance eosinophil apoptosis in the presence of survival-prolonging cytokines
The EC50 Values for the effects of trichostatin A on apoptosis in eosinophils and neutrophils.
79 ± 2
102 ± 1
93 ± 1
123 ± 9
92 ± 8
34 ± 10
97 ± 22
32 ± 17
99 ± 7
47 ± 15
100 ± 11
20 ± 5
87 ± 9
31 ± 10
Glucocorticoids are known to partially antagonize the survival-prolonging action of IL-5 or GM-CSF on eosinophils. However, this effect of glucocorticoids is abolished when the cytokine is used at higher concentrations [14, 20, 21, 22]. For example, recently, we reported that budesonide (1 μM) partly antagonizes cytokine-afforded survival in the presence of low but not in the presence of high concentrations of IL-5 . The maximal response and the EC50 values (Table 1) of TSA were almost similar independently of the concentration of GM-CSF, suggesting that the cellular targets of TSA are different from that of glucocorticoids.
To evaluate whether the ability to antagonize cytokine-afforded eosinophil survival is not related to TSA only, we employed other pharmacological inhibitors of HDACs. Another general HDAC inhibitor, apicidin (0.1 - 10 μM) antagonized GM-CSF-mediated eosinophil survival by inducing apoptosis with an EC50 of 427 ± 42 nM (Figure 2B). MC-1293, a commercially available HDAC1 inhibitor, antagonized GM-CSF-mediated eosinophil survival only partially at high (10 μM) drug concentrations (Figure 2C). Another HDAC inhibitor, MS-275 (0.1-1 μM), at concentrations known to inhibit HDAC1  did not affect GM-CSF-afforded eosinophil survival. In contrast, at higher concentrations (10-100 μM) known to inhibit HDAC3 , MS-275 enhanced apoptosis in GM-CSF-treated eosinophils (Figure 2D).
HDAC inhibitors enhance constitutive eosinophil apoptosis
In the absence of life-supporting cytokines, TSA increased the number of cells showing decreased relative DNA content suggesting apoptosis (Figure 2A, Table 1). Similarly, an increase in the number of cells presenting with the typical morphological features of apoptosis was found with TSA (percentage of apoptotic cells 11 ± 3 and 62 ± 8 in the absence and presence of 330 nM TSA, respectively, n = 5, P < 0.001). This was confirmed by showing an increase in the percentage of Annexin-V-positive cells in the absence and presence of TSA (330 nM) (15 ± 3% and 68 ± 8%, respectively, n = 6, P < 0.001).
HDAC inhibitors have additive effect on glucocorticoid-induced eosinophil apoptosis
Apicidin (1 nM-10 μM) also had an additive effect on budesonide-induced eosinophil apoptosis (Figure 4D). In contrast, MC-1293 (1 nM-10 μM, Figure 4E) failed to enhance budesonide-enhanced eosinophil apoptosis. MS-275 at higher concentrations (10-100 μM) had an additive effect on budesonide-induced eosinophil apoptosis (Figure 4F).
HDAC-inhibitors have an additive effect on Fas-induced eosinophil apoptosis
The effects of trichostatin A on Fas-induced eosinophil apoptosis.
Percentage of apoptotic cells
47 ± 4
65 ± 2##
Fas +trichostatin A 3.3 nM
67 ± 3
Fas +trichostatin A 33 nM
79 ± 2***
Fas +trichostatin A 330 nM
89 ± 1***
Effect of HDAC inhibitors on neutrophil apoptosis
In contrast to the enhancing effect on eosinphil apoptosis, glucocorticoids inhibit apoptosis in human neutrophils [13, 14, 24]. For example, budesonide inhibited neutrophil apoptosis, the percentages of apoptotic cells were 60 ± 5 and 42 ± 5 in the absence and presence of budesonide (1 μM), respectively (n = 6, P < 0.001, Figure 5C). TSA (3.3-330 nM) antagonized the inhibitory effect of budesonide (Figure 5C) on neutrophil apoptosis. This was confirmed by Annexin-V binding analysis (55 ± 4% vs 91 ± 1% Annexin V-positive cells, n = 6, P < 0.001). Furthermore, TSA antagonized fluticasone- (Figure 5D) and mometasone- (Figure 5E)-induced survival of neutrophils by inducing apoptosis. The EC50 values of TSA for antagonizing glucocorticoid-afforded survival in neutrophils were not different between the glucocorticoids (Table 1).
Pharmacological nature of the effect of HDAC inhibitors
HDAC expression in human eosinophils and neutrophils
HDAC activity in eosinophils and neutrophils
Acetylation of NF-κB p65 does not explain the apoptosis-inducing effect of TSA in human eosinophils
Effect of c-jun-N-terminal kinase and PI3K-Akt pathway inhibitors on TSA-induced apoptosis in human eosinophils
Inhibition of PI3K-Akt pathway by two chemically distinct inhibitors, namely wortmannin (10-100 nM) and LY294002 (5-50 μM) did not affect TSA-induced apoptosis in human eosinophils (n = 6, data not shown).
Involvement of caspases in TSA-induced apoptosis in human eosinophils
HDAC inhibitors enhance apoptosis in J774 macrophages
In the present study we show that HDAC inhibitors inhibit HDAC acitivity and induce apoptosis in human eosinophils and neutrophils in the absence and presence of survival-prolonging cytokines and glucocorticoids. Furthermore, we report that eosinophils and neutrophils express a different pattern of HDACs, namely the expression of HDAC2 and HDAC9 is higher in neutrophils than in eosinophils and the expression of HDAC8 is higher in eosinophils than in neutrophils. The mechanism of apoptosis-enhancing action of HDAC inhibitors in human eosinophils seems to involve JNK and caspases 3 and 6.
HDAC inhibitors have been reported to cause apoptotic cell death in a variety of cultured transformed cells, including human bladder, breast, prostate, lung, ovary and colon cancers and acute myelogenous leukemia . For example, HDAC inhibitors such as apicidin, sodium butyrate, suberoylanilide hydroxamic acid (SAHA) and TSA have been reported to reduce viability or induce apoptosis in HeLa cells [32, 33]. In contrast, normal cells are usually resistant to cell death caused by HDAC inhibitors [9, 10] and there is no previous data to describe the effects of HDAC inhibitors on apoptosis in human eosinophils or neutrophils. Supporting our results on the possible anti-inflammatory effects of HDAC inhibitors on granulocytes, recent in vivo data in animals suggest that HDAC inhibitors may have potential to act as anti-inflammatory agents. Choi and coworkers  demonstrated that TSA given prophylactically blocked OVA-induced airway hyper-responsiveness, as well as reduced the numbers of eosinophils in lavage fluid . Interestingly, HDAC inhibitors seem not to block the production of eosinophil life-supporting cytokines such as IL-5, but rather may enhance the activity of IL-5 promoter . Thus, it is tempting to speculate that as HDAC inhibitors may not reduce the concentrations of eosinophil survival-prolonging cytokines. The finding that TSA enhances apoptosis in the presence of IL-5- and GM-CSF, may, at least partly, explain the beneficial effects of TSA in models of eosinophilic inflammation.
Structurally distinct HDAC inhibitors were used. Unfortunately, the inhibitory profiles of HDAC inhibitors against all HDAC isoforms have not been thoroughly characterized. TSA has been reported to be a general HDAC inhibitor [31, 35, 36, 37]. HDAC1 selective inhibitors, MC-1293  and MS-275 at low concentrations  did not affect eosinophil apoptosis to a similar extent than TSA or apicidin. This probably excludes HDAC1 as a target of HDAC inhibitors. However, given that the effect of TSA in the HDAC activity assay experiments using nuclear extracts obtained from eosinophils or neutrophils revealed that the HDAC activity was reduced only by 50-60% even at 1 μM suggests either that granulocytes possess a TSA-insensitive HDAC e.g. HDAC4 or 7 or that HDACs are not the major target for HDAC inhibitors in these cells. The EC50 values for TSA in enhancing apoptosis in the presence or absence of glucocorticoids were different between eosinophils and neutrophils, whereas no difference was found in the EC50 values for TSA in the presence of GM-CSF. This suggests that there may be two or more HDACs responsible mediating these effects or that the effect may reflect the combined effect of two or more HDACs. The expression of HDAC2, HDAC8 and HDAC9 were different between eosinophils and neutrophils. This suggests that one or more of these HDACs may also be involved.
In malignant cell lines activation of caspase cascades as well as changes in the expression of Bcl-2 family members have been described [9, 10]. The exact mechanisms how the survival-prolonging cytokines IL-5 and GM-CSF induce eosinophil survival or glucocorticoids induce eosinophil death are not known in detail [3, 22, 30]. In fact, it is not even known whether glucocorticoid-induced apoptosis involves mainly transcriptional activation or repression . Mechanistically, inhibition of HDAC activity should lead to increased transcription. Treatment with HDAC inhibitors in an in vitro situation leads almost up to 10% of transcriptionally active genes having altered expression . Surprisingly, nearly an equal number of genes are repressed in their expression as those that are activated . Treatment with HDAC inhibitors in vitro causes an increase in the acetylation levels of histones in both normal and tumor cells, including melanocytes and melanoma cell lines . However, normal melanocytes are resistant to cell death caused by HDAC inhibitors, whereas most melanoma cell lines undergo apoptosis . This suggests that the difference between survival and death between normal and malignant cells may be due to acetylation of non-histone proteins rather than histones themselves [9, 10]. In eosinophils, NF-κB has been shown to be involved in the regulation of apoptosis . NF-κB assembly with IκB, as well as its DNA binding and transcriptional activity, are regulated by p300/CBP acetyltransferases that principally target Lys218, Lys221 and Lys310 [25, 26, 27]. This process is reciprocally regulated by HDACs and several HDAC inhibitors have been shown to activate NF-κB [25, 26, 27]. In fact, ineffectiveness of HDAC inhibitors to induce apoptosis in certain cell lines has been proposed to involve the transcriptional activation by acetylation of RelA/p65 subunit of NF-kB through the Akt pathway . However, we were not able to detect any increased acetylation of NF-kB p65 in response to TSA in human eosinophils. Similarly, inhibition of the PI3K-Akt pathway by pharmacological inhibitors did not modulate TSA-induced apoptosis. These results suggest that NF-kB p65 or PI3K-Akt pathway are not involved, but we cannot exclude other non-histone targets.
c-jun-N-terminal kinase (JNK) pathway has been proposed to be involved in spontaneous and nitric oxide- and orazipone-induced apoptosis of human eosinophils [3, 16, 17, 28]. Inhibition of JNK activity by the cell permeable inhibitory peptide L-JNKI1 almost completely abolished TSA-enhanced DNA breakdown, suggesting a role for JNK. Even though the involvement of caspases in apoptosis in general is well established, surprisingly little is known of the role caspases in human eosinophils [3, 30] and the actual caspases mediating apoptosis in human eosinophils remain largely unknown [3, 30]. General caspase inhibitors Q-Vd-OPh and Z-Asp-CH2-DCB completely antagonized the effect of TSA on apoptosis in human eosinophils similarly to inhibitors of caspases 6 and 3, whereas inhibition of caspase 8 had no effect. However, caspase inhibition also reduced spontaneous apoptosis as previously described . These results suggest a role for JNK and caspases 3 and 6, but not 8, in the mechanism of action of TSA in human eosinophils. This interpretation may be complicated by the fact that the specificity of these inhibitors for caspases 3, 6 and 8 has not been completely characterized. However, neither JNK nor caspases 3 and 6 appear specific for HDAC-inhibitor-induced apoptosis as they have been reported to affect spontaneous or induced apoptosis in human eosinophils [3, 16, 17, 28].
In contrast to the potentiation of glucocorticoid effects in eosinophils, in neutrophils TSA antagonized the survival-prolonging effect of glucocorticoids on neutrophil survival. In addition, the EC50 value for TSA for antagonism of glucocorticoid-induced survival in neutrophils was higher than that in eosinophils for enhancement of glucocorticoid-induced apoptosis. One might argue that the effect of HDAC inhibitors is non-specific in that they override the effects of any survival-prolonging factor in granulocytes.
Accumulation, activation and delayed death of neutrophils at the inflamed site has recently been implicated in the pathogenesis of COPD, severe asthma and asthma exacerbations . We found that TSA antagonized GM-CSF-afforded neutrophil survival by inducing apoptosis. In addition, TSA enhanced apoptosis in the absence and presence of glucocorticoids in neutrophils. We were not able to identify any studies exploring the effects of TSA on neutrophilic inflammation in the lung and based on our results such studies are warranted.
HDAC inhibitors are unique in the sense that they antagonize cytokine-afforded survival of eosinophils and neutrophils despite the vast amount of literature that indicates that they are not toxic towards several types of normal non-malignant cell lines [9, 10]. In fact, the published phase I-II clinical trials suggest that HDAC inhibitors: 1. inhibit HDAC activity in vivo in humans and 2. show moderate to good tolerability in humans [40, 41, 42, 43, 44]. Thus, it is tempting to speculate that HDAC inhibitors might be used to treat also eosinophilic and/or neutrophilic inflammation.
Macrophages are considered to be important in the removal of apoptotic cells. The finding that TSA at similar concentrations induced apoptosis also in a macrophage cell-line suggests that removal of apoptotic cells in the lungs could be impaired. However, in addition to macrophages, lung epithelial cells have been implicated in the removal of apoptotic eosinophils  and A549 lung epithelial cells have been reported to be insensitive to apoptosis induced by HDAC inhibitors .
Taken together, our results suggest that HDAC inhibitors such as TSA enhance apoptosis both in the presence and absence of survival-prolonging cytokines in eosinophils and neutrophils. In addition, TSA has an additive effect on apoptosis in the presence of glucocorticoids in eosinophils and antagonizes glucocorticoid-induced neutrophil survival. The mechanism of action in eosinophils involves c-jun-N-terminal kinase and caspases 3 and 6. Thus, HDAC inhibitors have anti-eosinophilic and anti-neutrophilic properties and are possible drug candidates to treat eosinophilic or neutrophilic inflammation.
Supported by Tampere Tuberculosis Foundation (Finland), the Academy of Finland, the Finnish Anti-Tuberculosis Association Foundation (Finland), and the Medical Research Funds of Tampere University Hospital (Finland) and Seinäjoki Central Hospital (Finland). The skilful technical help of Ms. Elina Heiskanen is gratefully acknowledged.
- 6.Vignola AM, Chanez P, Chiappara G, Siena L, Merendino A, Reina C: Evaluation of apoptosis of eosinophils, macrophages, and T lymphocytes in mucosal biopsy specimens of patients with asthma and chronic bronchitis. J Allergy Clin Immunol. 1999, 103: 563-73. 10.1016/S0091-6749(99)70225-3.PubMedCrossRefGoogle Scholar
- 7.Adcock IM: Histone deacetylase inhibitors as novel anti-inflammatory agents. Curr Opin Invest Drugs. 2006, 7: 966-73.Google Scholar
- 15.Kankaanranta H, De Souza PM, Barnes PJ, Salmon M, Giembycz MA, Lindsay MA: SB 203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils. J Pharm Exp Ther. 1999, 290: 621-628.Google Scholar
- 17.Zhang X, Moilanen E, Lahti A, Hämäläinen M, Giembycz MA, Barnes PJ, Lindsay MA, Kankaanranta H: Regulation of eosinophil apoptosis by nitric oxide: Role of c-Jun-N-terminal kinase and signal transducer and activator of transcription 5. J Allergy Clin Immunol. 2003, 112: 93-101. 10.1067/mai.2003.1587.PubMedCrossRefGoogle Scholar
- 23.Hu E, Dul E, Sung C-M, Chen Z, Kirkpatrick R, Zhang G-F, Johanson K, Liu R, Lago A, Hofmann G, Macarron R, de los Frailes M, Perez P, Krawiec J, Winkler J, Jaye M: Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharm Exp Ther. 2003, 307: 720-728. 10.1124/jpet.103.055541.CrossRefGoogle Scholar
- 26.Mayo MW, Denlinger CE, Broad RM, Yeung F, Reilly ET, Shi Y, Jones DR: Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kB through the Akt pathway. J Biol Chem. 2003, 278: 18980-18989. 10.1074/jbc.M211695200.PubMedCrossRefGoogle Scholar
- 29.Machida K, Inoue H, Matsumoto K, Tsuda M, Fukuyama S, Koto H, Aizawa H, Kureishi Y, Hara N, Nakanishi Y: Activation of PI3K-Akt pathway mediates antiapoptotic effects of β-adrenergic agonist in airway eosinophils. Am J Physiol Lung Cell Mol Physiol. 2005, 288: L860-L867. 10.1152/ajplung.00131.2004.PubMedCrossRefGoogle Scholar
- 38.Mai A, Massa S, Ragno R, Esposito M, Sbardella G, Nocca G, Scatena R, Jesacher F, Loidl P, Brosch G: Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation [abstract]. J Med Chem. 2002, 45: 1778-10.1021/jm011088+.PubMedCrossRefGoogle Scholar
- 40.Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, Germing U, Haas R, Gattermann N: Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia. Ann Hematol. 2005, 84 (suppl 1): 61-66. 10.1007/s00277-005-0026-8.PubMedCrossRefGoogle Scholar
- 41.Hauschild A, Trefzer U, Garbe C, Kaehler K, Ugurel S, Kiecker F, Eigentler T, Krissel H, Schadendorf D: A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules [abstract]. J Clin Oncol. 2006, 24 (suppl): 8044-Google Scholar
- 42.Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, Rollins S, Tidwell ML, Greer J, Chung EJ, Gore SD, Sausville EA, Zwiebel J, Karp JE: Phase 1 and pharmacological study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood. 2007, 109: 2781-2790.PubMedPubMedCentralGoogle Scholar
- 43.Garcia-Manero G, Assouline S, Cortes J, Kantarjian H, Yang H, Newsome WM, Miller WH, Rousseau C, Kalita A, Liu J, Dubay M, Patterson TA, Li Z, Besterman JM, Reid G, Laille E, Martell RE, Minden MD: Phase I study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 2008, 112: 981-989. 10.1182/blood-2007-10-115873.PubMedPubMedCentralCrossRefGoogle Scholar
- 44.Siu LL, Pili R, Duran I, Messersmith WA, Chen EX, Sullivan R, MacLean M, King S, Brown S, Reid GK, Li Z, Kalita AM, Laille EJ, Besterman JM, Martell RE, Carducci MA: Phase I study of MGCD0103 given as three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol. 2008, 26: 1940-1947. 10.1200/JCO.2007.14.5730.PubMedPubMedCentralCrossRefGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.